Latest Breaking News On - Pieris pharmaceuticals inc view - Page 1 : comparemela.com

Pieris Pharmaceuticals, Inc : Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific

Pieris Pharmaceuticals, Inc : Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesStephens yoderSophie kornowskiExchange commissionPieris pharmaceuticalsPieris pharmaceuticals incCompany quarterly reports on formBoston pharmaceuticalsPieris pharmaceuticals inc viewSecurities exchangeBoston pharmaceutical sponsoredBoston pharmaceuticalLooking statementsSecurities actSecurities exchange actAnnual report

Pieris Pharmaceuticals, Inc : Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring

Pieris Pharmaceuticals, Inc : Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesStephen yoderPieris pharmaceuticalsPieris pharmaceuticals incCompany quarterly reports on formPieris pharmaceuticals inc viewNicolaus company incSecurities exchangeExchange commissionLooking statementsSecurities actSecurities exchange actAnnual reportQuarterly reportsRelations contactInc view

Pieris Pharmaceuticals, Inc : Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep Due to New Non-Clinical Safety Findings From 13-week Toxicology Study

Pieris Pharmaceuticals, Inc : Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep Due to New Non-Clinical Safety Findings From 13-week Toxicology Study
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesJoe patneaudeStephen yoderPieris pharmaceuticals inc viewPieris pharmaceuticalsSecurities exchangeExchange commissionCompany quarterly reports on formPieris pharmaceuticals incPieri presidentLooking statementsSecurities actSecurities exchange actAnnual reportQuarterly reportsRelations contact

Pieris Pharmaceuticals, Inc : Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference

BOSTON, MA / ACCESSWIRE / June 2, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology

New yorkUnited statesStephen yoderJoe patneaudePieris pharmaceuticalsPieris pharmaceuticals incPieris pharmaceuticals inc viewJefferies healthcare conferenceRelations contactInc view

Pieris Pharmaceuticals, Inc : Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference

BOSTON, MA / ACCESSWIRE / May 22, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology

United statesThe notchGewinn nurJoe patneaudeShane olwillInternational conferenceAmerican thoracic societyPieris pharmaceuticals inc viewExchange commissionCompany quarterly reports on formSecurities exchangePieris pharmaceuticalsPieris pharmaceuticals incChief development officerSecurities actSecurities exchange act